ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

KZIA Kazia Therapeutics Ltd

0.3887
0.01875 (5.07%)
Apr 26 2024 - Closed
Delayed by 15 minutes

Period:

Draw Mode:

Volume 55,572
Bid Price 0.3702
Ask Price 0.39
News -
Share Name Share Symbol Market Stock Type
Kazia Therapeutics Ltd KZIA NASDAQ Depository Receipt
  Price Change Price Change % Share Price Last Trade
0.01875 5.07% 0.3887 19:00:00
Open Price Low Price High Price Close Price Previous Close
0.3646 0.357 0.389 0.37 0.36995
Trades Shares Traded VWAP Financial Volume Average Volume
166 55,572  0.3746732  20,821 -
Last Trade Type Quantity Price Currency
16:21:32 25  0.3701 USD

Kazia Therapeutics Ltd Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
0 228.03M - 0 -20.47M - -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

News Kazia Therapeutics

Date Time Source Heading
3/21/202407:52PR Newswire (US)Kazia Therapeutics licenses paxalisib to Sovargen for..
3/13/202407:00PR Newswire (US)Kazia announces presentation of new data at AACR Annual..
2/21/202415:19Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]
2/21/202408:19Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and..
2/21/202406:30PR Newswire (US)Kazia Therapeutics Reports Early Conclusion of Clinical..
2/14/202414:41Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial..
2/12/202417:35Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial..
2/05/202423:15Edgar (US Regulatory)Form EFFECT - Notice of Effectiveness
2/05/202415:19Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]
1/18/202415:30Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and..
1/18/202406:30PR Newswire (US)KAZIA CONTINUES BOARD RENEWAL WITH TWO NEW APPOINTMENTS
1/12/202415:05Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and..
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No KZIA Message Board. Create One! See More Posts on KZIA Message Board See More Message Board Posts

KZIA Historical

Period † Open High Low VWAP Avg. Daily Vol Change %
1 Week0.000.000.000.0000.000.00%
1 Month0.000.000.000.0000.000.00%
3 Months0.000.000.000.0000.000.00%
6 Months0.000.000.000.0000.000.00%
1 Year0.000.000.000.0000.000.00%
3 Years0.000.000.000.0000.000.00%
5 Years0.000.000.000.0000.000.00%

Kazia Therapeutics Ltd is an oncology-focused biotechnology company, developing innovative anti-cancer drugs. The group is developing GDC-0084, a potential treatment for glioblastoma; Cantrixil, being developed for the treatment of ovarian cancer; and Others.

Your Recent History

Delayed Upgrade Clock